Barclays PLC Purchases 23,398 Shares of Inogen, Inc. (NASDAQ:INGN)

Barclays PLC raised its holdings in shares of Inogen, Inc. (NASDAQ:INGN) by 72.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 55,508 shares of the medical technology company’s stock after purchasing an additional 23,398 shares during the period. Barclays PLC owned 0.23% of Inogen worth $539,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Divisadero Street Capital Management LP lifted its holdings in Inogen by 682.3% in the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after buying an additional 2,046,766 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Inogen by 312.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after acquiring an additional 132,287 shares during the period. AQR Capital Management LLC raised its position in shares of Inogen by 29.3% during the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock valued at $4,642,000 after acquiring an additional 129,307 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Inogen in the 2nd quarter valued at $651,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Inogen in the 2nd quarter worth $457,000. Institutional investors own 89.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a report on Friday, December 20th. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Tuesday.

Inogen Stock Performance

INGN opened at $10.47 on Friday. The firm’s fifty day moving average is $9.53 and its two-hundred day moving average is $9.93. The firm has a market cap of $249.40 million, a PE ratio of -4.65 and a beta of 1.02. Inogen, Inc. has a twelve month low of $5.08 and a twelve month high of $13.33.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.